Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFM Regimen in Relapsed/Refractory Follicular Lymphoma
NCT00169208Phase 2Completed
- Sponsor
- Lymphoma Study Association
- Start
- Apr 2001
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, fludarabine, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in follicular lymphoma (FL), sponsored by Lymphoma Study Association. Started Apr 2001; status: completed.
02
Drugs
rituximabfludarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00169208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169208.